Tag Archives: Mene Pangalos

AstraZeneca reçoit l’approbation de l’UE pour son Saphnelo, le seul nouveau médicament depuis plus d’une décennie pour les patients atteints de lupus érythémateux disséminé

(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé l’approbation par l’Union européenne (UE) de son médicament Saphnelo (anifrolumab) en tant que traitement d’appoint pour le traitement des patients … Read the full press release

AstraZeneca receives EU approval for its Saphnelo, the only new medicine in over a decade for patients with systemic lupus erythematosus

(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an European Union (EU) approval for its Saphnelo (anifrolumab) medicine as an add-on therapy for the treatment of adult patients with … Read the full press release

The only new medicine in over a decade for patients with systemic lupus erythematosus gets Food and Drug Administration (FDA) approval

(PRESS RELEASE) CAMBRIDGE, 2-Aug-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish science-led biopharmaceutical company, has announced that its Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus … Read the full press release

Hyperkalaemia: Japan’s Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma

Hyperkalaemia - Japan’s Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma

(PRESS RELEASE) CAMBRIDGE, 26-Mar-2020 — /EuropaWire/ — Science-led biopharmaceutical group AstraZeneca (LSE/STO/NYSE: AZN) has announced that its Lokelma (sodium zirconium cyclosilicate) is now approved in Japan. It is used for the treatment of patients with hyperkalaemia (elevated levels of potassium … Read the full press release

AstraZeneca will use BenevolentAI’s advanced AI to dive into its disease area expertise and massive datasets to gain insights into the complex disease biology

AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney disease and idiopathic pulmonary fibrosis (PRESS RELEASE) CAMBRIDGE / LONDON, 30-Apr-2019 — /EuropaWire/ — New partnership, announced today, by AstraZeneca … Read the full press release